The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
Related Posts
Delta Air Lines slashes earnings outlook on weaker U.S. demand, sending shares lower
Delta Air Lines cut its first-quarter revenue and profit forecasts, citing weaker consumer and corporate travel demand.
Novo Nordisk’s Wegovy weight loss drug sales soar 67% in second quarter
Novo Nordisk last week cut its full-year guidance and named Mike Doustdar as its new CEO.
Pro Talks: Charles Schwab’s Liz Ann Sonders on her approach to the second half of 2025
CNBC’s Dominic Chu speaks to Liz Ann Sonders, chief investment strategist at Charles Schwab, to get her playbook for the second half of the year. […]